ENERGIZE THE FIGHT.
FDA APPROVES TK2D THERAPY
The U.S. Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease TK2d. “It’s hard to put into words what today’s decision means for patients living with TK2d,” said UMDF President and CEO Kristen Clifford. READ MORE >>
Our Mito Champions
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Need to Connect with Us?
Call the Support Line: (888) 900-6486
UMDF Joins Fellow Mito PAGs on Letter to Senate Special Committee Regarding FDA Flexibility for DCA
Ask the Mito Doc – November 2025; Q&A
Ask the Mito Doc - November 2025 Q&A All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Topic: Genetic Testing in Mitochondrial Disease - What Patients and...
Your November UMDF Newsletter: Celebrating a TK2d Therapy Approval, MELAS Survey, Mito Books, and More
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.